Togo develops anti-hepatitis treatment
Lome - Togolese scientists announced on Thursday they had developed and put on the market an effective medical product against all forms of hepatitis.
Known as Hepantivir, the product is produced on the basis of a molecule, securinin. Scientists say they have put the product on the market in Togo and other countries of the region.
A research summary said the product is used against chronic hepatitis B and C to prevent serious complications such as cirrhosis and liver cancer.
Securinin also helped to prevent acute cases becoming chronic, it said.
Treatment with the new medicine costs the equivalent of about eight French francs (R7,80) per day without hospitalisation. Length of treatment varies from one to six months, depending on the severity of the case. - Sapa-AFP